Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 16708987 | METHODS FOR PURIFYING PROTEINS | December 2019 | November 2023 | Allow | 47 | 2 | 1 | No | No |
| 16660635 | MULTISTEP FINAL FILTRATION | October 2019 | September 2023 | Allow | 47 | 1 | 0 | Yes | No |
| 16536777 | INDIRECT HOMOGENEOUS MOBILITY SHIFT ASSAYS FOR THE DETECTION OF BIOLOGICS IN PATIENT SAMPLES | August 2019 | August 2023 | Allow | 48 | 2 | 0 | No | No |
| 16459187 | SYSTEMS AND METHODS FOR PREPARING A POLYPEPTIDE FROM A MIXTURE | July 2019 | September 2023 | Allow | 50 | 2 | 0 | Yes | No |
| 16433763 | ION EXCHANGE MEMBRANE CHROMATOGRAPHY | June 2019 | November 2023 | Allow | 54 | 2 | 1 | Yes | No |
| 16349617 | METHOD FOR PURIFYING ANTIBODY | May 2019 | January 2024 | Abandon | 56 | 1 | 0 | No | No |
| 16373293 | AFFINITY LIGANDS AND METHODS RELATING THERETO | April 2019 | January 2024 | Abandon | 57 | 3 | 0 | Yes | No |
| 16358779 | METHODS AND COMPOSITIONS FOR TREATING COMPLEMENT-ASSOCIATED DISORDERS | March 2019 | June 2023 | Allow | 51 | 2 | 0 | No | No |
| 16275821 | PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS | February 2019 | January 2024 | Abandon | 59 | 2 | 1 | No | No |
| 16258294 | FC-RECEPTOR BASED AFFINITY CHROMATOGRAPHY | January 2019 | February 2023 | Allow | 49 | 3 | 1 | Yes | No |
| 15121676 | ANTIBODY PURIFICATION PROCESS | August 2016 | September 2018 | Allow | 25 | 2 | 0 | Yes | No |
| 15135730 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | April 2016 | December 2016 | Allow | 8 | 1 | 0 | No | No |
| 15135757 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | April 2016 | January 2017 | Allow | 9 | 1 | 0 | No | No |
| 14902851 | Concentration and purification of hydrophobins and antibodies with a phase separation method | January 2016 | February 2019 | Allow | 38 | 1 | 0 | Yes | No |
| 14894993 | PROTEIN PURIFICATION PROCESS | November 2015 | September 2018 | Allow | 34 | 2 | 1 | Yes | No |
| 14769098 | CHROMATOGRAPHIC PURIFICATION OF ANTIBODIES FROM CHROMATIN-DEFICIENT CELL CULTURE HARVESTS | August 2015 | March 2018 | Allow | 31 | 2 | 1 | Yes | No |
| 14766131 | PROTEIN PURIFICATION METHODS | August 2015 | March 2018 | Allow | 31 | 1 | 1 | No | No |
| 14819334 | ENHANCED PURIFICATION OF ANTIBODIES AND ANTIBODY FRAGMENTS BY APATITE CHROMATOGRAPHY | August 2015 | December 2017 | Allow | 29 | 1 | 0 | Yes | No |
| 14766123 | METHODS FOR REDUCING AGGREGATE LEVELS IN PROTEIN PREPARATIONS BY TREATMENT WITH THIO-HETEROCYCLIC CATIONS | August 2015 | April 2018 | Allow | 32 | 2 | 1 | No | No |
| 14555060 | CHROMATOGRAPHIC PURIFICATION OF IMMUNOGLOBULIN G PREPARATIONS WITH PARTICLES HAVING MULTIMODAL FUNCTIONALITIES | November 2014 | September 2017 | Allow | 34 | 1 | 1 | Yes | No |
| 14493488 | REIMMUNIZATION AND ANTIBODY DESIGN | September 2014 | November 2017 | Allow | 37 | 1 | 1 | Yes | No |
| 14255931 | LASER-BASED VACCINE ADJUVANTS | April 2014 | April 2018 | Allow | 48 | 3 | 0 | Yes | No |
| 14131944 | METHOD FOR PREPARING A CONCENTRATE OF POLYVALENT IMMUNOGLOBULIN | January 2014 | June 2017 | Allow | 41 | 2 | 1 | Yes | No |
| 13857867 | ANTIBODIES TO IL-6 AND THEIR USES | April 2013 | May 2014 | Allow | 13 | 0 | 1 | Yes | No |
| 13781009 | HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | February 2013 | September 2013 | Allow | 6 | 0 | 0 | Yes | No |
| 13668515 | ANTI-INFLAMMATORY ANTIBODIES AND USES THEREFOR | November 2012 | February 2015 | Allow | 28 | 0 | 1 | Yes | No |
| 13636410 | FILLER FOR AFFINITY CHROMATOGRAPHY AND METHOD FOR ISOLATING IMMUNOGLOBULIN | September 2012 | March 2015 | Allow | 30 | 1 | 0 | No | No |
| 13391124 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE AND PATHOGENIC DISEASES | July 2012 | June 2015 | Allow | 39 | 1 | 1 | Yes | No |
| 13454296 | ANTIBODIES TO IL-6 AND THEIR USES | April 2012 | December 2012 | Allow | 8 | 0 | 1 | Yes | No |
| 13380477 | METHODS OF STIMULATING LIVER REGENERATION | March 2012 | February 2015 | Allow | 38 | 1 | 1 | No | No |
| 13146876 | CD93 OR USE OF SOLUBLE FRAGMENT THEREOF | October 2011 | November 2014 | Allow | 40 | 2 | 1 | Yes | No |
| 13177114 | METHOD FOR SEPARATING FRACTIONS OF AVIAN EGGS EXCLUSIVELY CONTAINING IGA AND IGM ANTIBODIES | July 2011 | August 2013 | Allow | 25 | 0 | 1 | Yes | No |
| 13063579 | METHOD FOR PROVIDING A �-LACTOGLOBULIN PRODUCT AND AN alpha-ENRICHED WHEY PROTEIN ISOLAT, | May 2011 | February 2015 | Allow | 47 | 2 | 1 | Yes | No |
| 12992701 | PROCESS FOR PRODUCING MILK FRACTIONS RICH IN SECRETORY IMMUNOGLOBULINS | February 2011 | October 2013 | Allow | 35 | 1 | 1 | Yes | No |
| 12745537 | HUMAN MONOCLONAL NICOTINE SPECIFIC ANTIBODIES | January 2011 | August 2012 | Allow | 27 | 0 | 1 | Yes | No |
| 12962101 | ANTI-INFLAMMATORY ANTIBODIES AND USES THEREFOR | December 2010 | August 2012 | Allow | 20 | 1 | 1 | Yes | No |
| 12903053 | METHODS OF PURIFYING ANTI A BETA ANTIBODIES | October 2010 | February 2013 | Allow | 28 | 2 | 0 | Yes | No |
| 12810585 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | June 2010 | January 2013 | Allow | 31 | 1 | 1 | Yes | No |
| 12670778 | METHODS FOR THE TREATMENT OR PREVENTION OF HEMORRHAGIC CONDITIONS | May 2010 | November 2013 | Allow | 46 | 3 | 1 | Yes | No |
| 12676283 | METHOD OF DETERMINING FUNCTIONAL DEFICIENCIES IN THE COMPLEMENT SYSTEM | April 2010 | May 2014 | Allow | 51 | 2 | 1 | Yes | No |
| 12452772 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE | April 2010 | November 2014 | Allow | 57 | 3 | 1 | Yes | No |
| 12732979 | Methods for isolation of Antibody Binding to Cells | March 2010 | September 2013 | Allow | 42 | 5 | 0 | Yes | No |
| 12628263 | ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF | December 2009 | February 2012 | Allow | 27 | 1 | 1 | Yes | No |
| 12584931 | Methods for Quantifying Protein Leakage From Protein Based Affinity Chromatography Resins | September 2009 | October 2012 | Allow | 37 | 0 | 1 | Yes | No |
| 12523516 | CD9-SPECIFIC HUMAN ANTIBODIES | July 2009 | February 2012 | Allow | 31 | 1 | 1 | Yes | No |
| 12480991 | ANTIBODIES TO IL-6 AND THEIR USES | June 2009 | January 2012 | Allow | 31 | 1 | 1 | Yes | No |
| 12472034 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | May 2009 | September 2013 | Allow | 52 | 4 | 1 | Yes | No |
| 12387794 | Affinity matured CRIg variants | May 2009 | February 2012 | Abandon | 33 | 3 | 1 | Yes | No |
| 12299670 | REIMMUNIZATION AND ANTIBODY DESIGN | April 2009 | June 2014 | Allow | 60 | 2 | 1 | Yes | No |
| 11813333 | HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION | March 2009 | October 2013 | Allow | 60 | 2 | 1 | Yes | No |
| 12322938 | BREAKING IMMUNOLOGICAL TOTERANCE WITH A GENETICALLY ENCODED UNNATURAL AMINO ACID | February 2009 | July 2012 | Allow | 41 | 2 | 1 | Yes | No |
| 12092346 | USE OF COMPLEMENT INHIBITORS TO TREAT OCULAR DISEASES | October 2008 | January 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 11715307 | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | March 2007 | October 2012 | Allow | 60 | 1 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ROGERS, JAMES L works in Art Unit 1641 and has examined 53 patent applications in our dataset. With an allowance rate of 92.5%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner ROGERS, JAMES L's allowance rate of 92.5% places them in the 78% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by ROGERS, JAMES L receive 1.60 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ROGERS, JAMES L is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +13.4% benefit to allowance rate for applications examined by ROGERS, JAMES L. This interview benefit is in the 50% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 38.9% of applications are subsequently allowed. This success rate is in the 89% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 73.3% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.9% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.